CA
CRSP icon

Crewe Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Crewe Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.1K Hold
350
– – ﹤0.01% 631
2026
Q1 		$16.6K Buy
350
+100
+40% +$5.27K ﹤0.01% 554
2025
Q4 		$13.1K Hold
250
– – ﹤0.01% 567
2025
Q3 		$16.2K Buy
+250
New +$14.4K ﹤0.01% 537
2025
Q1 		– Sell
-300
Closed -$11.8K – 724
2024
Q4 		$11.8K Sell
300
-100
-25% -$4.72K ﹤0.01% 413
2024
Q3 		$18.8K Buy
400
+100
+33% +$5.07K ﹤0.01% 413
2024
Q2 		$16.2K Buy
300
+100
+50% +$5.78K ﹤0.01% 591
2024
Q1 		$13.6K Buy
+200
New +$14.3K ﹤0.01% 571

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Crewe Advisors's CRSP Position: Q2 2026 in Review

Crewe Advisors held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 350 shares worth $19.1K. The position accounts for ﹤0.01% of the portfolio, ranked #631.

Crewe Advisors first reported a position in CRSP in Q1 2024 and has held it in 8 quarters since. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Crewe Advisors held 350 shares of CRISPR Therapeutics worth $19.1K as of Q2 2026.
  • Crewe Advisors left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Crewe Advisors's portfolio in Q2 2026, its #631 holding.
  • Crewe Advisors first reported a position in CRISPR Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Crewe Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.